Vinflunine – an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study

2006

Vinflunine for Advanced Lung Cancer

Sample size: 63 publication Evidence: moderate

Author Information

Author(s): J Bennouna, J-L Breton, J-M Tourani, C Ottensmeier, M O'Brien, P Kosmidis, T E Huat, M-C Pinel, C Colin, J-Y Douillard

Primary Institution: Centre René Gauducheau

Hypothesis

Does vinflunine provide an effective treatment option for patients with advanced non-small-cell lung cancer who have previously been treated with platinum-based chemotherapy?

Conclusion

Vinflunine shows clinically relevant activity as a second-line treatment for patients with advanced non-small-cell lung cancer who have failed first-line platinum-based therapy.

Supporting Evidence

Vinflunine achieved a response rate of 7.9% in the intent-to-treat analysis.
Median overall survival was 7 months for patients treated with vinflunine.
58.3% of evaluable patients achieved disease control.
50% of patients experienced grade 3-4 neutropenia.

Takeaway

Vinflunine is a new medicine that helps some people with lung cancer when other treatments have not worked. It can make the cancer smaller and help people live longer.

Methodology

This was a multicentre, single-arm, phase II trial assessing the efficacy of vinflunine in patients with advanced non-small-cell lung cancer who had failed platinum-based therapies.